Gilead Sciences news

Ranked as top drug developer in CAR/TCR/TIL therapies space, indicating strong market position and leadership in this high-growth oncology segment

FDA approval of Bixlenvo addresses an underserved market segment, company raised 2026 HIV sales growth outlook to 9-10%, strong portfolio performance with Biktarvy and Descovy, Yeztugo expected to approach $1 billion in 2026 sales, and expanding lenacapavir pipeline offers multiple future growth opportunities.

Gilead received a Zacks Rank #1 (Strong Buy) rating based on a significant 40.4% increase in consensus earnings estimates over the past month, indicating strong analyst agreement on improving earnings prospects. Additionally, it has a Buy-equivalent average brokerage recommendation (ABR) of 1.52 with 71% Strong Buy ratings from 31 firms.

The article highlights Gilead's strong financial performance (4% revenue growth, 54.8% EPS growth), four promising drug launches in 2026, strategic acquisitions that diversify its pipeline beyond HIV, no major patent cliffs until 2036, attractive valuation at 15x forward earnings, and reliable dividend growth (11 consecutive years of increases). These factors suggest significant upside potential that current market valuation may not fully reflect.

Kite is expanding access to its CAR T-cell therapies through innovative infrastructure, demonstrating market growth strategy and commitment to reaching more eligible patients. The partnership positions Kite as a leader in scaling cell therapy adoption.

The discontinuation of the lung cancer trial represents a setback for the Trodelvy combination therapy program. However, positive Phase 3 HIV results provide some offset. The stock was down 2.28% at publication, reflecting net negative sentiment from the lung cancer trial failure.

The company achieved positive Phase 3 study results showing Livdelzi significantly improved ALP normalization in an underrepresented PBC patient population. The drug demonstrated a consistent safety profile with no new safety concerns. These results expand the evidence base for the drug and support regulatory discussions, representing meaningful clinical progress in liver disease treatment.

Strategic acquisitions demonstrate aggressive pipeline expansion in oncology and inflammation portfolios. However, stock was down 1.35% at publication, and technical analysis shows short-term weakness (trading below 20-day and 50-day SMAs), tempering the positive acquisition news.

Gilead acquires Ouro Medicines and gains control of gamgertamig, a differentiated BCMA×CD3 T cell engager with Fast Track and Orphan Drug designations showing transformative efficacy in severe autoimmune diseases. The collaboration with Galapagos provides development support and cost-sharing while Gilead retains global commercialization rights, leveraging its proven late-stage development and launch capabilities.

Strategic acquisition expands Gilead's inflammation and autoimmune disease portfolio with a promising clinical-stage asset (OM336) that has FDA Fast Track and Orphan Drug Designation, strengthening long-term growth prospects in a key therapeutic area.

Gilead acquires a clinical-stage asset with transformative efficacy data and FDA Fast Track/Orphan Drug designations, shares development costs with Galapagos through registrational studies, and retains sole worldwide commercialization rights (except Greater China), positioning it to capture significant value from a differentiated autoimmune therapy.

Gilead acquires Ouro Medicines and secures exclusive global commercialization rights (except Greater China) for OM336, a promising BCMA-targeted T-cell engager with orphan drug status and Fast Track designation. The partnership with Galapagos shares development costs and leverages Galapagos' expertise while Gilead retains commercial upside.

Announced acquisition of Arcellx to expand its oncology pipeline, building on existing 2022 collaboration. While strategically positive for pipeline expansion, the article does not provide specific sentiment indicators about Gilead's stock performance or investor reception.

Gilead is acquiring a promising cancer therapy company to strengthen its oncology portfolio and accelerate commercialization of anito-cel, a CAR T-cell therapy with positive clinical results.

Third-largest holding in IBBQ (7.85%). No specific performance commentary provided.

Mentioned among companies engaged in co-development partnerships, but no specific deal information or performance indicators are provided in the article.

Mentioned only as a valuation comparison point. No direct news impact.

Mentioned only as a valuation comparison point, with J&J trading at lower P/E multiples than Gilead. No specific performance or outlook information provided.

Listed as a top holding in BBH, but no specific analysis or sentiment indicators provided.

Gilead's Kite Pharma has two approved CAR T therapies (YESCARTA and TECARTUS) with established market presence and expanding indications. TECARTUS received full FDA approval in April 2026, and YESCARTA label was expanded in February 2026, positioning the company well in a growing market.

TECARTUS (brexucabtagene autoleucel) holds approximately 50% of 7MM CAR-T revenue in 2025, demonstrating market leadership in adult relapsed/refractory ALL. Strong uptake and established position support continued growth.

Gilead is noted as a significant competitor in the HIV market where GSK faces competition, indicating Gilead's strong position in this therapeutic area.

Mentioned as a competitor with Yescarta and Tecartus CAR T therapies, but no specific performance data or developments provided in the article.

Major key player in the monoclonal antibodies market positioned to benefit from market growth in oncology and immunology applications.

Partnering with MacroGenics on MGD024, expanding its oncology pipeline with an innovative immunotherapy approach for CML.

Third-largest holding in IBBQ (7.33%) but no independent analysis provided; sentiment reflects its role as a major biotech component.

Mentioned only in valuation comparison context.

Stepped up dealmaking with three acquisitions totaling over $12.6 billion spanning oncology and inflammation, gaining control of promising CAR-T and ADC assets to expand commercial potential.

Listed as a top holding in IBB. No specific performance or sentiment information provided; included for informational purposes only.

Mentioned as a major holding in BBH with substantial portfolio weight, representing established biotech leadership.

Key holding in both ETFs (7.12% in IBBQ, 12.94% in BBH) representing core sector exposure without independent sentiment assessment.

Top holding in IBBQ (7.12%), included as part of fund composition without specific performance commentary.

Krishnan Chellakarai, CISO at Gilead Sciences, received the CISO Large Enterprise ORBIE, recognizing outstanding information security leadership in a major pharmaceutical company.

Second-largest holding in BBH at 12.8%, a biotech company within the concentrated BBH portfolio.